Form 144 PTC THERAPEUTICS For: 17 November By Investing.com
This article from Investing.com announces the filing of Form 144 for PTC Therapeutics (PTCT) on November 17, 2026. Form 144 is typically filed by an insider of a company who intends to sell restricted stock. The article provides a brief notice of this financial event without further details.
PTC Therapeutics at Jefferies Global Healthcare Conference: growth broadens
PTC Therapeutics (PTCT) highlighted its significant transformation and growth in its Sephience launch at the Jefferies Global Healthcare Conference. The company reported strong Q3 2026 revenue of $182 million, an annualized run rate of $650 million, and is on track for cash flow breakeven in 2026 and sustainable profitability in 2027. Management projects a $2 billion-plus peak sales opportunity for Sephience, an oral PKU treatment, and discussed its global commercial progress and strategic approach to R&D and business development.
How $500 Million Buyback At PTC Therapeutics (PTCT) Has Changed Its Investment Story
PTC Therapeutics recently announced a US$500 million share repurchase program, which is expected to influence how investors perceive dilution risk and future capital allocation. The company's investment narrative relies on its rare disease pipeline, particularly Sephience and ST 920, to offset pressures in its Duchenne muscular dystrophy portfolio and achieve sustainable profitability. Analysts project significant revenue and earnings growth by 2029, suggesting a potential 54% upside, although some bearish analysts are more cautious in their outlook.
Why Everyone Is Watching PTC Therapeutics (PTCT) Today
PTC Therapeutics is gaining attention after releasing mixed fourth-quarter and full-year 2026 results, coupled with increased revenue guidance, driven by AI monetization and improved contract terms. The stock has seen a 9.12% 7-day return but a 12.31% decline over 90 days, despite a strong 3-year total shareholder return. Analysts view PTC Therapeutics as undervalued, with a fair value of $97.80, based on the potential of its rare disease assets and significant cash balance.
Weekly Recap: Up to $500M buyback and Citi raises target to $109
PTC Therapeutics, Inc. (PTCT) authorized a share buyback program of up to $500 million on November 3, 2026. Concurrently, Citigroup reiterated its Buy rating on the stock and increased its price target from $108 to $109. These developments indicate positive sentiment from both the company and analysts regarding PTCT's future performance.
PTC Therapeutics, Inc. (PTCT) Seasonal Returns Chart - Yahoo Finance
This article from Yahoo Finance provides a seasonal returns chart for PTC Therapeutics, Inc. (PTCT), showing the average monthly price return from 2016 to 2026. As of November 6, 2026, the stock closed at $65.44, experiencing a slight after-hours decline to $65.39.
PTC Therapeutics (PTCT) Stock Could Be Near Fair Value Today
PTC Therapeutics (PTCT) stock is currently trading around US$68.97 and appears to be roughly fairly valued based on its P/S ratio of 5.0x, which is below the wider biotech industry average. Despite a strong 252% share price increase over the past three years and lifted 2026 product revenue guidance, the market is assigning a lower revenue multiple to PTC Therapeutics compared to its peers. Analysts hold differing views, with some seeing further upside in the rare disease portfolio while others believe much of the growth is already priced in.
PTC Therapeutics Inc (BH3.SG) Seasonal returns chart - Yahoo Finance
This Yahoo Finance article presents a seasonal returns chart for PTC Therapeutics Inc (BH3.SG), displaying the average monthly price return from 2016 to 2026. The stock is listed on the Stuttgart exchange with a delayed quote. The article includes current market data for various global indices and cryptocurrencies.
Why PTC Therapeutics Bears Were Right Before The Drop
Despite headlines of record revenue and raised guidance, PTC Therapeutics shareholders are down 20.7% year-to-date. This article explores the contrasting bullish and cautious views on the company at the start of 2026, highlighting that while revenue grew, profitability remained a concern. The current price of US$60.88 means buyers must believe that new assets like Sephience and ST-920 can overcome the decline in older Duchenne drugs to justify the investment.
PTC Therapeutics Authorizes Share Repurchase Program of Up to $500 Million
PTC Therapeutics has announced that its board of directors has approved a share repurchase program, allowing the company to buy back up to $500 million of its common stock. The repurchases will be made at management's discretion and can occur through various transaction types. This program reflects the company's confidence in its future prospects while maintaining financial flexibility.
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference on November 16, 2026, and the Citi 2026 Global Healthcare Conference on December 1, 2026. Executives from the company will speak at these events, with presentations available via live webcast and archived on the PTC Therapeutics website. The company focuses on discovering and developing medicines for rare disorders.
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that its Board of Directors has authorized a share repurchase program of up to $500 million of its outstanding common stock. This program reflects the company's confidence in its strength and growth prospects, allowing it to invest in its shares while maintaining financial flexibility for existing programs and potential business development. Repurchases will be made at management's discretion through various methods, including open-market and privately negotiated transactions.
Citigroup maintains PTC Therapeutics at Buy, raises price target to $109 from $108
Citigroup has reiterated its "Buy" rating for PTC Therapeutics and increased its price target from $108 to $109, implying an 81.8% upside from its recent closing price. This adjustment follows several other analyst actions in the past month, with price targets ranging from $77 to $112.
Truist reiterates Hold on PTC Therapeutics stock after Q3 results By Investing.com
Truist Securities has reiterated a Hold rating on PTC Therapeutics (NASDAQ:PTCT) with a $62.00 price target following the company's Q3 2026 results. The firm's analysis suggests PTC Therapeutics is currently undervalued, trading near its 52-week low. The Hold rating reflects Truist's view on the company's commercial prospects for its product Sephience, which is entering a more mature growth phase.
PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To Loss
PTC Therapeutics (PTCT) stock slid approximately 7% after the company reported Q3 2026 results, returning to a quarterly loss despite a significant increase in total revenue to US$358 million, primarily driven by Sephience. While the company boasts US$2.13 billion in cash and raised its 2026 guidance for product and total revenue, investors reacted negatively to the shift from profit to loss, overshadowing the growth in its rare disease franchise and progress on pipeline milestones.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. announced the approval of non-statutory stock options for 9,620 shares and 11,535 restricted stock units (RSUs) to 13 new employees. These inducement grants, approved by the Compensation Committee on October 28, 2026, are a material component of the new hires' employment compensation under Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $63.02 per share and vest over four years, similar to the RSUs, which also vest over four years.
PTC Therapeutics, Inc. Stock 12‑Month Price Target Raised to $100.33, Implies 56% Upside
PTC Therapeutics, Inc.'s average price target has been increased from $97.81 to $100.33 by 15 analysts, implying a potential upside of approximately 56% from its Oct. 29 closing price. The consensus rating for the stock remains "Buy" among 16 covering analysts.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. announced inducement grants of non-statutory stock options for 9,620 shares and 11,535 restricted stock units to 13 new employees. These awards were approved on October 28, 2026, by the company's Compensation Committee, with an exercise price of $63.02 per share, consistent with Nasdaq Listing Rule 5635(c)(4). The grants are part of the new hires' employment compensation and vest over four years, subject to continued service.
RBC Capital maintains PTC Therapeutics at Sector Perform, raises price target to $77 from $75
RBC Capital has reiterated its "Sector Perform" rating for PTC Therapeutics (PTCT) and increased its price target from $75 to $77. This new target suggests a 19.5% upside from the stock's closing price on October 29. Investors can find more detailed analyst ratings and forecasts for PTCT on TradingView's platform.
PTC Therapeutics, Inc. (PTCT) Q3 Revenue $358M; 2026 Outlook Raised
PTC Therapeutics reported strong Q3 2026 revenue of $358 million, including $276 million in product revenue. Following these results, the company raised its 2026 total revenue guidance to $1.29–$1.32 billion and product revenue guidance to $960–$990 million. The positive outlook is primarily driven by the momentum from the Sephience launch and the acquisition of ST-920, with a Biologics License Application (BLA) expected in Q4 2026.
PTC Therapeutics Q3 2026 Earnings Call Transcript
PTC Therapeutics reported record Q3 2026 product revenue of $276 million, driving a raise in full-year 2026 revenue guidance to $1.29 to $1.32 billion, primarily due to the strong global launch and continued growth of Cephiance. The company is advancing its pipeline with the acquisition of a BLA-stage Fabry disease gene therapy asset, ST920, and progression in Huntington's disease and Friedrich's ataxia programs. PTC Therapeutics anticipates achieving cash flow breakeven in 2026 and plans to leverage its significant cash reserves for further strategic initiatives and business development opportunities.
PTC Therapeutics, Inc. - Common Stock (PTCT) Stock Price, News, Quote & History
PTC Therapeutics Inc. (PTCT) recently traded at $59.97, down 6.97%. The biopharmaceutical company focuses on rare diseases and cancer, leveraging expertise in RNA biology and translational medicine. Recent news highlights strong Q3 2026 earnings, increased revenue guidance, and plans to acquire a Fabry disease gene therapy asset.
Sephience brings in $182M as PTC Therapeutics (PTCT) raises its 2026 revenue outlook.
PTC Therapeutics reported strong third-quarter 2026 results, with total revenue reaching $357.8 million, including $182 million from Sephience. The company has consequently raised its full-year 2026 total revenue guidance to between $1.29 billion and $1.32 billion. Additionally, PTC Therapeutics is advancing its pipeline, including the acquisition of ST-920 for Fabry disease and progress in its Huntington's disease and Friedreich's ataxia programs.
PTC Therapeutics Q3 2026 Earnings Date and Estimates
PTC Therapeutics (NASDAQ: PTCT) is expected to report its Q3 2026 earnings on Thursday, October 29, 2026, after market close, with a conference call scheduled for 4:30 PM ET. Analysts anticipate earnings of $0.1431 per share on revenues of $305.05 million, reflecting a projected decrease in EPS but a significant increase in revenue compared to the prior year. The company has a history of beating EPS estimates, having done so in six of its last eight quarters.
PTC Therapeutics (PTCT) Shares Slid, So What Is Driving Attention Now?
PTC Therapeutics (PTCT) shares have recently declined, drawing attention to whether the stock's weakened price against a strong three-year performance presents a buying opportunity. The company is currently considered 38% undervalued by analysts, with a fair value estimate of $97.94, driven by its Sephience launch strategy and expanding healthcare coverage for rare disease treatments. However, the reliance on a narrow product set and potential regulatory setbacks for Translarna or slow Sephience uptake pose risks to this valuation.
Form 144 PTC THERAPEUTICS For: 24 October By Investing.com
This article announces the filing of Form 144 for PTC Therapeutics, Inc. (PTCT) on October 24. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The stock symbol PTCT is noted to be down 3.89%.
Form 144 PTC THERAPEUTICS For: 24 October By Investing.com
This article from Investing.com announces the filing of Form 144 for PTC Therapeutics, specifically for transactions on October 24th. The brief notice highlights the company's stock symbol PTCT and its current trading performance, showing a -3.89% change.
PTC Therapeutics, Inc. Estimates – NASDAQ:PTCT
The article provides an overview of PTC Therapeutics, Inc. (NASDAQ: PTCT) financial data and analyst estimates available on TradingView. It highlights sections for income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with various analyst estimates and visualize trends. The content explicitly states it is not investment advice and encourages users to conduct their own research.
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
Analysts are predicting a year-over-year decline in earnings for PTC Therapeutics (PTCT) in its upcoming quarterly report for the period ending September 2026, despite expectations of higher revenues. The biopharmaceutical company is forecasted to report earnings of $0.17 per share, a 15% decrease from the prior year, with revenues anticipated to reach $311.08 million, up 47.4%. The Zacks Earnings ESP indicates a bearish sentiment among analysts, with the Most Accurate Estimate lower than the consensus, suggesting a difficult prediction for an earnings beat.
PTC Therapeutics (PTCT) Projected to Release Earnings on Thursday
PTC Therapeutics (NASDAQ:PTCT) is anticipated to release its Q3 2026 earnings after market close on Thursday, October 29th. Analysts expect the company to report earnings of $0.2071 per share and revenue of $304.60 million. The biopharmaceutical company's previous quarter significantly outperformed expectations, with an EPS of $0.92 against a $0.24 consensus and revenue of $360.52 million, marking a 101.5% year-over-year increase.
PTC Therapeutics schedules October 29 results as stock trades below its high
PTC Therapeutics (PTCT) is scheduled to report its third-quarter 2026 financial results on October 29, 2026. The company's stock was trading at EUR 55.60 on October 20, 2026, significantly below its 52-week high, despite strong second-quarter revenue growth and positive analyst coverage from Truist Financial. Investors will be looking for further insights into the company's long-term growth and market position for its key therapies.
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
Argus has lowered its target price for PTC Therapeutics Inc. (PTCT) to $57.00, maintaining a HOLD investment rating. The report provides subratings across various categories including industry, management, safety, financial strength, growth, and value, with safety and value rated as low.
PTC Therapeutics director sells $149,036 in shares
A director at PTC Therapeutics (NASDAQ:PTCT), Michael Schmertzler, sold 2,500 shares of company stock worth $149,036 on October 14, 2026, through a pre-arranged trading plan. This sale occurred while PTCT shares were near their 52-week low. Despite the insider sale and unprofitability in the past year, analysts project profitability for PTC Therapeutics this year, with recent strong Q2 2026 earnings and strategic acquisitions supporting a positive outlook.
Truist sets USD 62.00 target for PTC Therapeutics stock
Truist Financial has initiated coverage on PTC Therapeutics (PTCT) with a Hold rating and a $62.00 price target, representing a 4.66% upside from its last Nasdaq closing price of $59.24. The company recently reported strong Q2 2026 revenues of $360.52 million, surpassing analyst estimates, and is set to announce Q3 2026 results on October 29, 2026. Despite positive revenue performance, PTCT's stock is trading near its 52-week low.
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Raised to "Strong-Buy" at UBS Group
UBS Group upgraded PTC Therapeutics (NASDAQ:PTCT) to a "strong-buy" rating, despite a broader analyst consensus of "moderate buy" and a recent dip in share price. The biopharmaceutical company reported stronger-than-expected quarterly results, with EPS of $0.92 against a $0.24 consensus and revenue up 101.5% year over year. Despite the positive financial performance, insiders have sold approximately $5.3 million in stock over the past three months under pre-arranged trading plans.
PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company Stock
PTC Therapeutics Director Michael Schmertzler recently sold 2,500 shares of the company's stock for $149,025 at an average price of $59.61. This transaction was part of a pre-arranged Rule 10b5-1 plan and follows a series of insider disposals by Schmertzler. Despite recent stronger-than-expected quarterly results and a "Moderate Buy" consensus rating from Wall Street, the stock is trading near its 52-week low.
Form 4 PTC Therapeutics Inc: Michael Schmertzler (Director) For: 14 October
This article reports on a Form 4 filing for PTC Therapeutics Inc., indicating a transaction by director Michael Schmertzler on October 14. Form 4 filings disclose changes in beneficial ownership of securities by company insiders, and this particular report highlights a director's activity related to PTC Therapeutics stock.
Form 4 PTC Therapeutics Inc: Michael Schmertzler (Director) For: 14 October
This article reports that Michael Schmertzler, a Director at PTC Therapeutics Inc., filed a Form 4 for October 14. The filing indicates insider transaction activity for the company.
PTCT Upgraded by UBS -- Price Target Raised to $90.00
UBS has upgraded PTC Therapeutics (PTCT) and raised its price target to $90.00, reflecting renewed confidence in the company's biotechnology developments. Despite this, GuruFocus indicates PTCT is 51.6% overvalued with a GF Value™ of $40.22 and a moderate GF Score™ of 59/100, largely due to strong momentum but weak profitability and growth. Significant insider selling also suggests caution for investors.
Planned sales of 2,118 and 382 PTC Therapeutics (PTCT) shares came from Section Six Partners.
PTC Therapeutics director Michael Schmertzler reported sales of 2,118 shares and 382 shares of common stock by Section Six Partners, L.P. on October 14, 2026. These sales, conducted under a Rule 10b5-1 plan, were at weighted-average prices of $59.52 and $60.14 per share, respectively. Schmertzler disclaimed beneficial ownership of the sold shares except for his pecuniary interest, while still holding 163,266 direct shares.
PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Truist Financial
Truist Financial has initiated coverage on PTC Therapeutics (NASDAQ:PTCT) with a "hold" rating and a $62 price target, despite overall analyst sentiment leaning towards a "Moderate Buy" with an average target of $95.07. The biopharmaceutical company recently reported strong quarterly earnings, beating consensus estimates with $0.92 EPS and $360.52 million in revenue, a 101.5% year-over-year increase. Insider selling activity, totaling approximately $5.17 million in the latest quarter, was also noted.
UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating
UBS has increased its price target for PTC Therapeutics (PTCT) from $80 to $90, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance.
UBS lifts PTC Therapeutics stock target to USD 90.00
UBS has increased its price target for PTC Therapeutics (PTCT) to USD 90.00 from USD 80.00, maintaining a Buy rating. This adjustment follows PTC Therapeutics' strong second-quarter 2026 revenue of USD 360.52 million, a 101.50 percent year-over-year increase, and a net profit of USD 83.50 million. The company's stock was trading at EUR 54.37 and had a market capitalization of USD 5.1 billion as of October 15, 2026.
UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating
UBS has increased its price target for PTC Therapeutics (PTCT) to $90 from $80, while maintaining a Buy rating on the stock. The company currently has an average rating of overweight and a mean price target of $100.33 among analysts. This article is a premium MT Newswires report, requiring a subscription to read in full.
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
PTC Therapeutics, Inc. (PTCT) announced it will host a webcast conference call on Thursday, October 29, 2026, at 4:30 p.m. ET to discuss its third quarter 2026 financial results and provide a business update. Interested parties can access the live webcast via the "Events & Presentations" page on the PTC website, with a replay available for 30 days, or register in advance for dial-in details. PTC Therapeutics is a global biopharmaceutical company focused on developing treatments for rare disorders.
A rare-disease drugmaker's Oct. 29 webcast includes a business update; replay stays online for 30 days.
PTC Therapeutics (NASDAQ: PTCT) announced it will host a webcast conference call on October 29, 2026, to report its third-quarter 2026 financial results and provide a business update. The call is scheduled for 4:30 p.m. ET, with a replay available on the company's website for 30 days. PTC Therapeutics is a global biopharmaceutical company focused on developing medicines for rare disorders.
PTC Therapeutics (PTCT) Stock Looks About Right At This Price
PTC Therapeutics (PTCT) has seen significant gains over three years, prompting an analysis of its current share price against its sales performance. The company's P/S ratio of 4.9x is below the biotech sector average, and the "Fair Ratio" framework suggests the stock is currently trading at an appropriate valuation based on its sales. The article highlights that future growth depends on continued execution in rare disease therapies and upcoming product launches.
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
PTC Therapeutics, Inc. announced it will host a webcast conference call on Thursday, October 29, 2026, at 4:30 p.m. ET to report its third-quarter 2026 financial results and provide a business update. Interested parties can access the live webcast via the Investors section of the PTC website, with a replay available for 30 days, or register to participate via phone. PTC Therapeutics is a global biopharmaceutical company focused on developing and commercializing medicines for rare disorders.
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
PTC Therapeutics, Inc. announced it will host a webcast conference call on Thursday, October 29, 2026, at 4:30 p.m. ET to report its third-quarter 2026 financial results and provide a business update. The event can be accessed via webcast on the company's website or by phone registration. PTC Therapeutics is a global biopharmaceutical company focused on developing medicines for rare disorders.
Form 4 PTC Therapeutics Inc: Mark Elliott Boulding (EXEC. VP AND CLO) For: 9 October
This article reports on a Form 4 filing for PTC Therapeutics Inc, detailing actions taken by Mark Elliott Boulding, Executive Vice President and Chief Legal Officer, on October 9. The report was published by Investing.com. It is a brief announcement without further details on the nature of the transaction.